150 related articles for article (PubMed ID: 24786972)
1. Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer.
Nisa L; Aebersold DM; Giger R; Zimmer Y; Medová M
Pharmacol Ther; 2014 Sep; 143(3):337-49. PubMed ID: 24786972
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
Lau PC; Chan AT
Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
5. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition.
Burtness B; Bauman JE; Galloway T
Lancet Oncol; 2013 Jul; 14(8):e302-9. PubMed ID: 23816296
[TBL] [Abstract][Full Text] [Related]
6. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
9. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
Cui JJ
J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
[TBL] [Abstract][Full Text] [Related]
10. c-Met targeting in advanced gastric cancer: An open challenge.
Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
[TBL] [Abstract][Full Text] [Related]
11. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
12. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
13. Understanding c-MET signalling in squamous cell carcinoma of the head & neck.
Szturz P; Raymond E; Abitbol C; Albert S; de Gramont A; Faivre S
Crit Rev Oncol Hematol; 2017 Mar; 111():39-51. PubMed ID: 28259294
[TBL] [Abstract][Full Text] [Related]
14. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
Liu X; Newton RC; Scherle PA
Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
[TBL] [Abstract][Full Text] [Related]
15. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
Lim YC; Kang HJ; Moon JH
Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851
[TBL] [Abstract][Full Text] [Related]
16. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
Maroun CR; Rowlands T
Pharmacol Ther; 2014 Jun; 142(3):316-38. PubMed ID: 24384534
[TBL] [Abstract][Full Text] [Related]
17. Thirty years of research on met receptor to move a biomarker from bench to bedside.
Furlan A; Kherrouche Z; Montagne R; Copin MC; Tulasne D
Cancer Res; 2014 Dec; 74(23):6737-44. PubMed ID: 25411347
[TBL] [Abstract][Full Text] [Related]
18. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
Finisguerra V; Prenen H; Mazzone M
Oncogene; 2016 Oct; 35(42):5457-5467. PubMed ID: 26996670
[TBL] [Abstract][Full Text] [Related]
20. Met as a therapeutic target in HCC: facts and hopes.
Giordano S; Columbano A
J Hepatol; 2014 Feb; 60(2):442-52. PubMed ID: 24045150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
